Hervé Françoise, Ghinea Nicolae, Scherrmann Jean-Michel
UFR Biomédicale, Université Paris Descartes, CNRS, UPR2228, 45 rue des Saints-Pères, 75270 Paris, France.
AAPS J. 2008 Sep;10(3):455-72. doi: 10.1208/s12248-008-9055-2. Epub 2008 Aug 26.
Adsorptive-mediated transcytosis (AMT) provides a means for brain delivery of medicines across the blood-brain barrier (BBB). The BBB is readily equipped for the AMT process: it provides both the potential for binding and uptake of cationic molecules to the luminal surface of endothelial cells, and then for exocytosis at the abluminal surface. The transcytotic pathways present at the BBB and its morphological and enzymatic properties provide the means for movement of the molecules through the endothelial cytoplasm. AMT-based drug delivery to the brain was performed using cationic proteins and cell-penetrating peptides (CPPs). Protein cationization using either synthetic or natural polyamines is discussed and some examples of diamine/polyamine modified proteins that cross BBB are described. Two main families of CPPs belonging to the Tat-derived peptides and Syn-B vectors have been extensively used in CPP vector-mediated strategies allowing delivery of a large variety of small molecules as well as proteins across cell membranes in vitro and the BBB in vivo. CPP strategy suffers from several limitations such as toxicity and immunogenicity--like the cationization strategy--as well as the instability of peptide vectors in biological media. The review concludes by stressing the need to improve the understanding of AMT mechanisms at BBB and the effectiveness of cationized proteins and CPP-vectorized proteins as neurotherapeutics.
吸附介导的转胞吞作用(AMT)为药物跨越血脑屏障(BBB)进入大脑提供了一种途径。血脑屏障很适合AMT过程:它既为阳离子分子与内皮细胞腔表面的结合和摄取提供了可能性,又为在无腔表面的胞吐作用提供了条件。血脑屏障存在的转胞吞途径及其形态学和酶学特性为分子通过内皮细胞质移动提供了手段。基于AMT的脑内药物递送是使用阳离子蛋白和细胞穿透肽(CPP)进行的。讨论了使用合成或天然多胺对蛋白质进行阳离子化,并描述了一些穿过血脑屏障的二胺/多胺修饰蛋白的实例。属于Tat衍生肽和Syn-B载体的两个主要CPP家族已广泛用于CPP载体介导的策略中,该策略允许在体外跨细胞膜以及在体内跨血脑屏障递送多种小分子以及蛋白质。与阳离子化策略一样,CPP策略存在一些局限性,例如毒性和免疫原性,以及肽载体在生物介质中的不稳定性。综述最后强调需要加强对血脑屏障处AMT机制的理解,以及阳离子化蛋白和CPP载体化蛋白作为神经治疗药物的有效性。